(Q36407215)

14 August 2017

1 reference

title

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus (English)

1 reference

14 August 2017

1 reference

Curtis Triplitt

1

1 reference

14 August 2017

Alison Wright

series ordinal

2

1 reference

14 August 2017

Elaine Chiquette

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

26

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

360-374

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon and the A cell: physiology and pathophysiology (first two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

GIP biology and fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Studies of pancreatic alpha cell function in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Role and integration of mechanisms controlling gastric emptying

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Disordered gastric motor function in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Rapid gastric emptying of a solid pancake meal in type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Gut peptides and type 2 diabetes mellitus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Glucagon physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.360

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.3.360

1 reference

14 August 2017

1 reference